A citation-based method for searching scientific literature

Ken Lee Chin, Richard Ofori-Asenso, Ingrid Hopper, Thomas G von Lueder, Christopher M Reid, Sophia Zoungas, Bing H Wang, Danny Liew. Cardiovasc Res 2019
Times Cited: 19







List of co-cited articles
121 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
68

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
52

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
52

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
973
31

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
764
31

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.
Sanjay K Banerjee, Kenneth R McGaffin, Núria M Pastor-Soler, Ferhaan Ahmad. Cardiovasc Res 2009
109
26

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
132
26

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
707
26

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1).
Lubing Zhou, Ellen V Cryan, Michael R D'Andrea, Stanley Belkowski, Bruce R Conway, Keith T Demarest. J Cell Biochem 2003
114
21

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
171
21

Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport.
Rebekah Lambert, Sarah Srodulski, Xiaoli Peng, Kenneth B Margulies, Florin Despa, Sanda Despa. J Am Heart Assoc 2015
45
15

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li,[...]. Cardiovasc Diabetol 2019
72
15

Functional effects of glucose transporters in human ventricular myocardium.
Dirk von Lewinski, Robert Gasser, Peter P Rainer, Marie-Sophie Huber, Bastian Wilhelm, Ulrich Roessl, Tobias Haas, Andrae Wasler, Michael Grimm, Egbert Bisping,[...]. Eur J Heart Fail 2010
26
15

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
195
15

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Javad Habibi, Annayya R Aroor, James R Sowers, Guanghong Jia, Melvin R Hayden, Mona Garro, Brady Barron, Eric Mayoux, R Scott Rector, Adam Whaley-Connell,[...]. Cardiovasc Diabetol 2017
93
15

Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target.
Alessandra Di Franco, Giulia Cantini, Alessia Tani, Raffaele Coppini, Sandra Zecchi-Orlandini, Laura Raimondi, Michaela Luconi, Edoardo Mannucci. Int J Cardiol 2017
54
15


Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma, Ankit Garg, Andrew T Yan, Anup K Gupta, Mohammed Al-Omran, Andre Sabongui, Hwee Teoh, C David Mazer, Kim A Connelly. Diabetes Care 2016
95
15

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar, James McLaren, Søren L Kristensen, David Preiss, John J McMurray. Diabetologia 2016
156
15

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
Petar M Seferović, Mark C Petrie, Gerasimos S Filippatos, Stefan D Anker, Giuseppe Rosano, Johann Bauersachs, Walter J Paulus, Michel Komajda, Francesco Cosentino, Rudolf A de Boer,[...]. Eur J Heart Fail 2018
167
15

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
799
15

The failing heart--an engine out of fuel.
Stefan Neubauer. N Engl J Med 2007
15


2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
15

Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia/reperfusion injury.
Zhao Li, Vineet Agrawal, Mohun Ramratnam, Ravi K Sharma, Stephen D'Auria, Abigail Sincoular, Margurite Jakubiak, Meredith L Music, William J Kutschke, Xueyin N Huang,[...]. Cardiovasc Res 2019
21
10

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
Hiroaki Kusaka, Nobutaka Koibuchi, Yu Hasegawa, Hisao Ogawa, Shokei Kim-Mitsuyama. Cardiovasc Diabetol 2016
61
10

SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy.
Sanjay K Banerjee, David W Wang, Rodrigo Alzamora, Xueyin N Huang, Núria M Pastor-Soler, Kenneth R Hallows, Kenneth R McGaffin, Ferhaan Ahmad. J Mol Cell Cardiol 2010
55
10

NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1.
Magali Balteau, Nicolas Tajeddine, Carole de Meester, Audrey Ginion, Christine Des Rosiers, Nathan R Brady, Caroline Sommereyns, Sandrine Horman, Jean-Louis Vanoverschelde, Philippe Gailly,[...]. Cardiovasc Res 2011
69
10

Chronic Pressure Overload Induces Cardiac Hypertrophy and Fibrosis via Increases in SGLT1 and IL-18 Gene Expression in Mice.
Naoko Matsushita, Nanae Ishida, Miho Ibi, Maki Saito, Atsushi Sanbe, Hisashi Shimojo, Satoshi Suzuki, Hermann Koepsell, Yasuchika Takeishi, Yoshihiro Morino,[...]. Int Heart J 2018
14
14


Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors.
Sarayut Lahnwong, Siriporn C Chattipakorn, Nipon Chattipakorn. Cardiovasc Diabetol 2018
47
10

Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.
Guanghong Jia, Michael A Hill, James R Sowers. Circ Res 2018
268
10

Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice.
Yusuke Kashiwagi, Tomohisa Nagoshi, Takuya Yoshino, Toshikazu D Tanaka, Keiichi Ito, Tohru Harada, Hiroyuki Takahashi, Masahiro Ikegami, Ryuko Anzawa, Michihiro Yoshimura. PLoS One 2015
54
10

Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ryuichi Ohgaki, Ling Wei, Kazunori Yamada, Taiki Hara, Chiaki Kuriyama, Suguru Okuda, Kiichiro Ueta, Masaharu Shiotani, Shushi Nagamori, Yoshikatsu Kanai. J Pharmacol Exp Ther 2016
33
10


Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts.
Liping Meng, Hiroyasu Uzui, Hangyuan Guo, Hiroshi Tada. Mol Med Rep 2018
8
25

Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients.
Dirk von Lewinski, Peter P Rainer, Robert Gasser, Marie-Sophie Huber, Mounir Khafaga, Bastian Wilhelm, Tobias Haas, Heinrich Mächler, Ulrich Rössl, Burkert Pieske. Metabolism 2010
31
10


Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
10

Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice.
Ronglih Liao, Mohit Jain, Lei Cui, Jessica D'Agostino, Francesco Aiello, Ivan Luptak, Soeun Ngoy, Richard M Mortensen, Rong Tian. Circulation 2002
204
10

Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
Kim A Connelly, Yanling Zhang, Jean-François Desjardins, Kerri Thai, Richard E Gilbert. Cardiovasc Diabetol 2018
14
14


Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.
Nikole J Byrne, Nirmal Parajuli, Jody L Levasseur, Jamie Boisvenue, Donna L Beker, Grant Masson, Paul W M Fedak, Subodh Verma, Jason R B Dyck. JACC Basic Transl Sci 2017
63
10


Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
83
10

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Subodh Verma, C David Mazer, Mohammed Al-Omran, Silvio E Inzucchi, David Fitchett, Uwe Hehnke, Jyothis T George, Bernard Zinman. Circulation 2018
72
10

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
245
10

The implications of therapeutic complexity on adherence to cardiovascular medications.
Niteesh K Choudhry, Michael A Fischer, Jerry Avorn, Joshua N Liberman, Sebastian Schneeweiss, Juliana Pakes, Troyen A Brennan, William H Shrank. Arch Intern Med 2011
174
10




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.